A Comparison of Jurkat Cell-Reactive Anti-T Lymphocyte Globulin and Fetal Anti-Thymocyte Globulin Preparations in the Treatment of Aplastic Anemia

Objective: The aim of this study was to investigate the success rate and effects on survival of different anti-thymocyte globulin (ATG) preparations in patients diagnosed with aplastic anemia. Subjects and Methods: Of the total 24 patients included in the study, 12 were male and 12 female with a median age of 44 years (range 16–72). Nine patients received Lymphoglobulin , 7 Thymoglobulin and ATG-Fresenius (ATG-F). There was no significant difference between the three treatment groups in terms of severity of aplastic anemia. Results: The estimated 6-month survival rates for ATG-F, Lymphoglobulin and Thymoglobulin groups were 42.9, 77.8 and 71.4%, respectively. The difference in overall survival rates between groups was not significant, most likely due to the low number of patients. The most striking result was that none of the patients in the ATG-F preparation group showed any response to treatment. The ATG-F group was found to have a significantly inferior response rate (p = 0.07). Received: February 16, 2010 Accepted: November 8, 2010 Dr. Songul Serefhanoglu Hacettepe University Hospital Department of Internal Medicine , Division of Hematology TR–06030 Ankara (Turkey) Tel. +90 312 305 1453, Fax +90 312 305 1536, E-Mail dr.songul1978 @ yahoo.com © 2011 S. Karger AG, Basel 1011–7571/11/0204–0341$38.00/0 Accessible online at: www.karger.com/mpp D ow nl oa de d by : 54 .7 0. 40 .1 1 11 /1 8/ 20 17 7 :0 8: 26 P M